James A Russell

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7891687/publications.pdf

Version: 2024-02-01

117	12,080	53751 45	25770 108
papers	citations	h-index	g-index

121	121	121	9037
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Vasopressin versus Norepinephrine Infusion in Patients with Septic Shock. New England Journal of Medicine, 2008, 358, 877-887.	13.9	1,711
2	Fluid resuscitation in septic shock: A positive fluid balance and elevated central venous pressure are associated with increased mortality*. Critical Care Medicine, 2011, 39, 259-265.	0.4	1,257
3	Management of Sepsis. New England Journal of Medicine, 2006, 355, 1699-1713.	13.9	995
4	Beneficial Effects of Short-term Vasopressin Infusion during Severe Septic Shock. Anesthesiology, 2002, 96, 576-582.	1.3	895
5	The Effects of Ibuprofen on the Physiology and Survival of Patients with Sepsis. New England Journal of Medicine, 1997, 336, 912-918.	13.9	831
6	The effects of vasopressin on hemodynamics and renal function in severe septic shock: a case series. Intensive Care Medicine, 2001, 27, 1416-1421.	3.9	640
7	Physiology of Vasopressin Relevant to Management of Septic Shock. Chest, 2001, 120, 989-1002.	0.4	593
8	PCSK9 is a critical regulator of the innate immune response and septic shock outcome. Science Translational Medicine, 2014, 6, 258ra143.	5.8	287
9	Toll-like Receptor 1 Polymorphisms Affect Innate Immune Responses and Outcomes in Sepsis. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 710-720.	2.5	258
10	Interaction of vasopressin infusion, corticosteroid treatment, and mortality of septic shock*. Critical Care Medicine, 2009, 37, 811-818.	0.4	234
11	Guidelines for the Diagnosis and Management of Critical Illness-Related Corticosteroid Insufficiency (CIRCI) in Critically Ill Patients (Part I): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017. Critical Care Medicine, 2017, 45, 2078-2088.	0.4	234
12	Guidelines for the diagnosis and management of critical illness-related corticosteroid insufficiency (CIRCI) in critically ill patients (Part I): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017. Intensive Care Medicine, 2017, 43, 1751-1763.	3.9	220
13	The effects of vasopressin on acute kidney injury in septic shock. Intensive Care Medicine, 2010, 36, 83-91.	3.9	206
14	Sepsis: frontiers in diagnosis, resuscitation and antibiotic therapy. Intensive Care Medicine, 2016, 42, 1958-1969.	3.9	151
15	An Endotoxin Tolerance Signature Predicts Sepsis and Organ Dysfunction at Initial Clinical Presentation. EBioMedicine, 2014, 1, 64-71.	2.7	140
16	Critical illness-related corticosteroid insufficiency (CIRCI): a narrative review from a Multispecialty Task Force of the Society of Critical Care Medicine (SCCM) and the European Society of Intensive Care Medicine (ESICM). Intensive Care Medicine, 2017, 43, 1781-1792.	3.9	132
17	Protein C â^'1641 AA is associated with decreased survival and more organ dysfunction in severe sepsis*. Critical Care Medicine, 2007, 35, 12-17.	0.4	130
18	Hyperchloremia and moderate increase in serum chloride are associated with acute kidney injury in severe sepsis and septic shock patients. Critical Care, 2016, 20, 315.	2.5	130

#	Article	IF	Citations
19	Albumin versus crystalloid for pump priming in cardiac surgery: Meta-analysis of controlled trials. Journal of Cardiothoracic and Vascular Anesthesia, 2004, 18, 429-437.	0.6	111
20	Effect of Selepressin vs Placebo on Ventilator- and Vasopressor-Free Days in Patients With Septic Shock. JAMA - Journal of the American Medical Association, 2019, 322, 1476.	3.8	107
21	Interleukin-10 Haplotype Associated With Increased Mortality in Critically Ill Patients With Sepsis From Pneumonia But Not in Patients With Extrapulmonary Sepsis. Chest, 2005, 128, 1690-1698.	0.4	103
22	The Association of Interleukin 6 Haplotype Clades With Mortality in Critically Ill Adults. Archives of Internal Medicine, 2005, 165, 75.	4.3	102
23	Vasopressin in septic shock: an individual patient data meta-analysis of randomised controlled trials. Intensive Care Medicine, 2019, 45, 844-855.	3.9	97
24	Selepressin, a novel selective vasopressin V1A agonist, is an effective substitute for norepinephrine in a phase IIa randomized, placebo-controlled trial in septic shock patients. Critical Care, 2017, 21, 213.	2.5	93
25	Lipopolysaccharide Is Cleared from the Circulation by Hepatocytes via the Low Density Lipoprotein Receptor. PLoS ONE, 2016, 11, e0155030.	1.1	92
26	Vasopressor therapy in critically ill patients with shock. Intensive Care Medicine, 2019, 45, 1503-1517.	3.9	91
27	Pathophysiology of Septic Shock. Critical Care Clinics, 2018, 34, 43-61.	1.0	78
28	Î²₂-Adrenergic Receptor Gene Polymorphism Is Associated with Mortality in Septic Shock. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 143-149.	2.5	74
29	Vasopressin in vasodilatory and septic shock. Current Opinion in Critical Care, 2007, 13, 383-391.	1.6	73
30	The Cardiopulmonary Effects of Vasopressin Compared With Norepinephrine in Septic Shock. Chest, 2012, 142, 593-605.	0.4	72
31	A global perspective on vasoactive agents in shock. Intensive Care Medicine, 2018, 44, 833-846.	3.9	69
32	Vasopressin Compared with Norepinephrine Augments the Decline of Plasma Cytokine Levels in Septic Shock. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 356-364.	2.5	65
33	Heparin-binding protein is important for vascular leak in sepsis. Intensive Care Medicine Experimental, 2016, 4, 33.	0.9	64
34	Leucyl/Cystinyl Aminopeptidase Gene Variants in Septic Shock. Chest, 2011, 139, 1042-1049.	0.4	63
35	Cholesteryl Ester Transfer Protein Influences High-Density Lipoprotein Levels and Survival in Sepsis. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 854-862.	2.5	62
36	The intensive care medicine research agenda on septic shock. Intensive Care Medicine, 2017, 43, 1294-1305.	3.9	61

#	Article	IF	Citations
37	Vasopressin and Its Immune Effects in Septic Shock. Journal of Innate Immunity, 2010, 2, 446-460.	1.8	60
38	Serious Adverse Events Associated With Vasopressin and Norepinephrine Infusion in Septic Shock*. Critical Care Medicine, 2014, 42, 1812-1820.	0.4	57
39	Inhibition of Cholesteryl Ester Transfer Protein Preserves High-Density Lipoprotein Cholesterol and Improves Survival in Sepsis. Circulation, 2021, 143, 921-934.	1.6	55
40	Current practice and evolving concepts in septic shock resuscitation. Intensive Care Medicine, 2022, 48, 148-163.	3.9	55
41	The Septic Shock 3.0 Definition and Trials: A Vasopressin and Septic Shock Trial Experience*. Critical Care Medicine, 2017, 45, 940-948.	0.4	54
42	Critical Illness-Related Corticosteroid Insufficiency (CIRCI): A Narrative Review from a Multispecialty Task Force of the Society of Critical Care Medicine (SCCM) and the European Society of Intensive Care Medicine (ESICM). Critical Care Medicine, 2017, 45, 2089-2098.	0.4	53
43	Protein C rs2069912 C allele is associated with increased mortality from severe sepsis in North Americans of East Asian ancestry. Human Genetics, 2008, 123, 661-663.	1.8	52
44	Elevated Plasma Angiopoietin-2 Levels Are Associated With Fluid Overload, Organ Dysfunction, and Mortality in Human Septic Shock. Critical Care Medicine, 2016, 44, 2018-2027.	0.4	52
45	The Central Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Septic Pathogen Lipid Transport and Clearance. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 1275-1286.	2.5	50
46	Association of angiotensin II type 1 receptor-associated protein gene polymorphism with increased mortality in septic shock*. Critical Care Medicine, 2011, 39, 1641-1648.	0.4	45
47	Cardiac ischemia in patients with septic shock randomized to vasopressin or norepinephrine. Critical Care, 2013, 17, R117.	2.5	43
48	Heparin-Binding Protein (HBP). Shock, 2017, 48, 313-320.	1.0	43
49	A Single Nucleotide Polymorphism in NF-Î°B Inducing Kinase Is Associated with Mortality in Septic Shock. Journal of Immunology, 2011, 186, 2321-2328.	0.4	42
50	Vasopressin in septic shock. Critical Care Medicine, 2007, 35, S609-S615.	0.4	40
51	Cytokines and Signaling Molecules Predict Clinical Outcomes in Sepsis. PLoS ONE, 2013, 8, e79207.	1.1	39
52	The Meta-Genome of Sepsis: Host Genetics, Pathogens and the Acute Immune Response. Journal of Innate Immunity, 2014, 6, 272-283.	1.8	38
53	Designing phase 3 sepsis trials: application of learned experiences from critical care trials in acute heart failure. Journal of Intensive Care, 2016, 4, 24.	1.3	38
54	Plasma cytokine levels predict response to corticosteroids in septic shock. Intensive Care Medicine, 2016, 42, 1970-1979.	3.9	35

#	Article	IF	Citations
55	Is There a Good MAP for Septic Shock?. New England Journal of Medicine, 2014, 370, 1649-1651.	13.9	34
56	Days alive and free as an alternative to a mortality outcome in pivotal vasopressor and septic shock trials. Journal of Critical Care, 2018, 47, 333-337.	1.0	34
57	Rationale and Design of an Adaptive Phase 2b/3 Clinical Trial of Selepressin for Adults in Septic Shock. Selepressin Evaluation Programme for Sepsis-induced Shockâ€"Adaptive Clinical Trial. Annals of the American Thoracic Society, 2018, 15, 250-257.	1.5	31
58	Association between chronic exposure to air pollution and mortality in the acute respiratory distress syndrome. Environmental Pollution, 2017, 224, 352-356.	3.7	30
59	Vasopressor Therapy in the Intensive Care Unit. Seminars in Respiratory and Critical Care Medicine, 2021, 42, 059-077.	0.8	30
60	Molecular Mechanisms of Sepsis. Contributions To Microbiology, 2011, 17, 48-85.	2.1	28
61	Reduced Proprotein convertase subtilisin/kexin 9 (PCSK9) function increases lipoteichoic acid clearance and improves outcomes in Gram positive septic shock patients. Scientific Reports, 2019, 9, 10588.	1.6	28
62	Longitudinal Plasma Proteomics Analysis Reveals Novel Candidate Biomarkers in Acute COVID-19. Journal of Proteome Research, 2022, 21, 975-992.	1.8	27
63	CETP genetic variant rs1800777 (allele A) is associated with abnormally low HDL-C levels and increased risk of AKI during sepsis. Scientific Reports, 2018, 8, 16764.	1.6	26
64	Acute Cardiac Injury in Coronavirus Disease 2019 and Other Viral Infectionsâ€"A Systematic Review and Meta-Analysis. Critical Care Medicine, 2021, 49, 1558-1566.	0.4	26
65	Early Liberal Fluids for Sepsis Patients Are Harmful. Critical Care Medicine, 2016, 44, 2258-2262.	0.4	25
66	Short-Term Organ Dysfunction Is Associated With Long-Term (10-Yr) Mortality of Septic Shock. Critical Care Medicine, 2016, 44, e728-e736.	0.4	23
67	Inotropes and vasopressors: more than haemodynamics!. British Journal of Pharmacology, 2012, 165, 2009-2011.	2.7	19
68	Selepressin in Septic Shock. Critical Care Medicine, 2016, 44, 234-236.	0.4	19
69	Genetic Polymorphisms in Sepsis and Cardiovascular Disease. Chest, 2019, 155, 1260-1271.	0.4	18
70	Decreased left ventricular contractility during porcine endotoxemia is not prevented by ibuprofen. Critical Care Medicine, 1996, 24, 815-819.	0.4	18
71	The Understanding and Management of Organism Toxicity in Septic Shock. Journal of Innate Immunity, 2018, 10, 502-514.	1.8	17
72	Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors in COVID-19: Meta-analysis/Meta-regression Adjusted for Confounding Factors. CJC Open, 2021, 3, 965-975.	0.7	15

#	Article	IF	Citations
73	Advances in Sepsis Research. Clinics in Chest Medicine, 2015, 36, 521-530.	0.8	14
74	Genomics and pharmacogenomics of sepsis: so close and yet so far. Critical Care, 2016, 20, 185.	2.5	14
75	Is Heparin-Binding Protein Inhibition a Mechanism of Albuminâ€™s Efficacy in Human Septic Shock?. Critical Care Medicine, 2018, 46, e364-e374.	0.4	14
76	Very Low Density Lipoprotein Receptor Sequesters Lipopolysaccharide Into Adipose Tissue During Sepsis. Critical Care Medicine, 2020, 48, 41-48.	0.4	13
77	Vasopressors During Sepsis. Clinics in Chest Medicine, 2016, 37, 251-262.	0.8	12
78	Vasopressin versus norepinephrine in septic shock: a propensity score matched efficiency retrospective cohort study in the VASST coordinating center hospital. Journal of Intensive Care, 2018, 6, 73.	1.3	12
79	Early May Be Better: Early Low-Dose Norepinephrine in Septic Shock. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 1049-1051.	2.5	12
80	Angiotensin II for the Treatment of High-Output Shock 3 (ATHOS-3): protocol for a phase III, double-blind, randomised controlled trial. Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine, 2017, 19, 43-49.	0.0	12
81	Gene expression in human sepsis: what have we learned?. Critical Care, 2010, 15, 121.	2.5	11
82	Renin-Angiotensin System Pathway Therapeutics Associated With Improved Outcomes in Males Hospitalized With COVID-19*. Critical Care Medicine, 2022, 50, 1306-1317.	0.4	10
83	Potential for overuse of corticosteroids and vasopressin in septic shock. Critical Care, 2012, 16, 447.	2.5	8
84	Vasopressin, Norepinephrine, and Vasodilatory Shock after Cardiac Surgery. Anesthesiology, 2017, 126, 9-11.	1.3	8
85	Intensive care medicine in 2050: vasopressors in sepsis. Intensive Care Medicine, 2018, 44, 1130-1132.	3.9	8
86	Personalized Blood Pressure Targets in Shock: What If Your Normal Blood Pressure Is â€œLowâ€?. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 10-12.	2.5	8
87	Beta-blockers in septic shock to optimize hemodynamics? Yes. Intensive Care Medicine, 2016, 42, 1607-1609.	3.9	7
88	Using multiple 'omics strategies for novel therapies in sepsis. Intensive Care Medicine, 2018, 44, 509-511.	3.9	7
89	Study protocol for a multicentre, prospective cohort study of the association of angiotensin II type 1 receptor blockers on outcomes of coronavirus infection. BMJ Open, 2020, 10, e040768.	0.8	7
90	Activated protein C as disease-modifying therapy in antenatal preeclampsia: An open-label, single arm safety and efficacy trial. Pregnancy Hypertension, 2018, 13, 121-126.	0.6	5

#	Article	IF	Citations
91	Treatment with a polymyxin B filter to capture endotoxin in sepsis patients: is there a signal for therapeutic efficacy?. Intensive Care Medicine, 2019, 45, 282-283.	3.9	5
92	Assessing the Course of Organ Dysfunction Using Joint Longitudinal and Time-to-Event Modeling in the Vasopressin and Septic Shock Trial. , 2020, 2, e0104.		5
93	Noncanonical Nuclear Factor Kappa B (NF-Î²B) Signaling and Potential for Therapeutics in Sepsis. Current Infectious Disease Reports, 2013, 15, 364-371.	1.3	4
94	Prolonged QTc affects short-term and long-term outcomes in patients with normal left ventricular function undergoing cardiac surgery. Journal of Thoracic and Cardiovascular Surgery, 2014, 147, 1627-1633.	0.4	4
95	How much excess fluid impairs outcome of sepsis?. Intensive Care Medicine, 2017, 43, 680-682.	3.9	4
96	Toward Increased Understanding of the Steroid Controversy in Septic Shock. Critical Care Medicine, 2019, 47, 1677-1679.	0.4	4
97	The Specific Organism: Not Bacterial Gram Type: Drives the Inflammatory Response in Septic Shock. Journal of Innate Immunity, 2020, 12, 182-190.	1.8	4
98	The Potential for Increasing Risk of Consent Refusal in COVID-19 Trials: Considering Underlying Reasons and Responses. Annals of the American Thoracic Society, 2022, 19, 1446-1447.	1.5	4
99	Trials in adult critical care that show increased mortality of the new intervention: Inevitable or preventable mishaps?. Annals of Intensive Care, 2016, 6, 17.	2.2	3
100	When and how to use predictive biomarkers for corticosteroid treatment of septic shock. Critical Care, 2018, 22, 318.	2.5	3
101	Single Nucleotide Variant in FAS Associates With Organ Failure and Soluble Fas Cell Surface Death Receptor in Critical Illness. Critical Care Medicine, 2022, 50, e284-e293.	0.4	3
102	Organ dysfunction and death in patients admitted to hospital with COVID-19 in pandemic waves 1 to 3 in British Columbia, Ontario and Quebec, Canada: a cohort study. CMAJ Open, 2022, 10, E379-E389.	1.1	3
103	Early goal-directed therapy: from discovery through enthusiasm to equipoise?. Intensive Care Medicine, 2015, 41, 1676-1678.	3.9	2
104	Pharmacogenomic biomarkers do not predict response to drotrecogin alfa in patients with severe sepsis. Annals of Intensive Care, 2018, 8, 16.	2.2	2
105	Physician Culture and Vasopressin Use in Septic Shock. Annals of the American Thoracic Society, 2016, 13, 1677-1679.	1.5	2
106	Could Altered Leukocyte Gene Expression Profile in Trauma Patients Guide Immune Interventions to Prevent Gram-Negative Bacteremia?*. Critical Care Medicine, 2014, 42, 1550-1551.	0.4	1
107	Innovation and safety in critical care: should we collaborate with the industry? Pro. Intensive Care Medicine, 2018, 44, 2276-2278.	3.9	1
108	Terlipressin or norepinephrine in septic shock: do we have the answer?. Journal of Thoracic Disease, 2019, 11, S1270-S1273.	0.6	1

#	Article	IF	Citations
109	Improving Bed Utilization in a Cohort of Bariatric Surgical Patients Using a Perioperative Obstructive Sleep Apnea Treatment and Bed Triage Protocol. Obesity Surgery, 2022, 32, 1926-1934.	1.1	1
110	Pharmacogenomics in sepsis and septic shock. Drug Development Research, 2005, 64, 181-194.	1.4	0
111	Metagenomics and Innate Immunity - A Unique Partnership or a Battlefield?. Journal of Innate Immunity, 2014, 6, 251-252.	1.8	0
112	C-TERMINAL PORTION OF PRO-ARGININE-VASOPRESSIN (CT-PRO-AVP) AS A PREDICTIVE BIOMARKER IN SEPSIS. Shock, 2015, 44, 381-382.	1.0	0
113	In Reply. Anesthesiology, 2018, 128, 230-231.	1.3	0
114	Once or Twice Daily Screening for Weaning the Critically Illâ€"Have We Set Our Sights Too Low?*. Critical Care Medicine, 2019, 47, 874-875.	0.4	0
115	Independent Clinical Criteria in Medicine. Chest, 2020, 157, 1418-1419.	0.4	0
116	How have genomics informed our understanding of critical illness?. , 2020, , 23-35.e1.		0
117	Virus Meets Host: SARS-CoV-2 Pathogenesis. World Scientific Series in Global Healthcare Economics and Public Policy, 2022, , 35-49.	0.1	0